

|                                    |   |                           |            |
|------------------------------------|---|---------------------------|------------|
| <b>Department:</b>                 | Pharmacy Management                     | <b>Original Approval:</b> | 01/28/2013 |
| <b>Policy &amp; Procedure No:</b>  | PM515                                   | <b>Last Approval:</b>     | 03/03/2023 |
| <b>Policy and Procedure Title:</b> | Transition Process Policy and Procedure |                           |            |
| <b>Approved By:</b>                | Clinical Services Leadership Team       |                           |            |
| <b>Dependencies:</b>               | N/A                                     |                           |            |

## Purpose

This policy defines the manner in which Community Health Plan of Washington (CHPW) transitions new members into its Washington State health program to ensure continuity of care for the Medicaid line of business.

## Policy & Procedure

CHPW's Transition Process policy accommodates the immediate prescription needs of qualified members and prescriptions. It allows sufficient time to ensure a smooth transition to a therapeutically equivalent medication with the prescriber, or the completion of an exception request to maintain coverage of an existing drug based on medical necessity.

## Temporary Fill

CHPW allows a temporary supply of most non-formulary drugs. Also allowed is a formulary drug that remains on formulary, but to which new prior authorization or step therapy restrictions have been added, for members who are eligible for transition.

## Transition Terms

CHPW will cover up to a maximum 90-day temporary supply of medication in single fills of 30-day supplies or less for newly enrolled members in Apple Health during their first 90 days of enrollment. If needed, CHPW will cover additional refills after the initial 90 days in the plan.

## Written Notice

CHPW will provide members with written notice regarding transition process within 7 days of the temporary fill.

Data contained in this document is considered confidential and proprietary information and its duplication, use, or disclosure is prohibited without prior approval of Community Health Plan of Washington.

## **Administration**

The transition policy is administered by CHPW's Pharmacy Benefit Manager (PBM) as described in the following PBM transition procedures:

### **General Procedures**

1. The transition procedures will apply to non-formulary medications and formulary medications that require prior authorization, including antipsychotics, antidepressants, and antiepileptic medications.
2. PBM will implement hard edits in the claims adjudication process to require pharmacy attestation to allow transition fills for eligible drugs and members. The reject messaging will provide the override code necessary for the pharmacy to input at point of sale if they attest the member is established on the medication. Enrollee's eligibility will be determined based on an eligibility days element. If an enrollee is not eligible, the claim will not meet transition fill criteria and it will be appropriately rejected with no transition fill override available. The pharmacy will receive appropriate messaging at the point of sale corresponding to the rejection. If a claim is approved under transition fill criteria, it will include messaging indicating that the claim was paid pursuant to transition fill requirements at the point of sale and an approved letter will be sent to the enrollee as specified in this procedure.
3. CHPW will be responsible for making prior authorization, formulary exception request forms, and the plan's transition fill policy available upon request to enrollees, authorized representatives, and prescribing physicians by mail, fax, and plan web sites.

### **Procedures For New Enrollees**

1. A brand-new prescription for a non-formulary drug will not be treated any differently than an ongoing prescription for a non-formulary drug once the dispensing pharmacy attests the member is established on the medication at the point of sale. The transition period extends for the first 90 days of eligibility in the plan. PBM will implement hard edits to verify the new enrollee is in the transition period and require the pharmacy to input the override codes attesting the member is established on the medication for non-formulary or prior-authorization-required eligible medications to process.
2. If the prescribed medication is non-formulary or requires prior authorization, the new enrollee may receive up to a 90-day supply in single fills of 30-day supplies or less. However, transition fills may be rejected or dispensed for less than the prescribed amount for safety reasons including quantity level limits or drug utilization edits based on approved product labeling. In such cases, messaging will instruct the pharmacy to lower the quantity and to resubmit the claim using a code

Data contained in this document is considered confidential and proprietary information and its duplication, use, or disclosure is prohibited without prior approval of Community Health Plan of Washington.

for a quantity level limit. The code will enable a unique notification to be sent to the new enrollee advising them of the quantity level limit or drug utilization edit as may be required.

- Quantity overrides will be available for members who are transferring in or out of an IP facility to prevent breaks in treatment.
  - Transition fills for opioid medications are limited to a 30-day supply within the first 90 days of enrollment.
3. Once the claim adjudicates, a transition letter will be mailed within 7 days from processing date. The text of the letter will include:
- An explanation the transition supply provided is temporary and may not be refilled unless a formulary exception is approved;
  - The enrollee should work with CHPW as well as his or her health care provider to identify appropriate therapeutic alternatives that are on CHPW's formulary; and
  - The member has the right to request a formulary exception.

### **Transition Period Extensions**

CHPW supports the Washington State Health Care Authority requirement to continue to provide necessary drugs to enrollees via an extension of the transition period. This will be done on a case-by-case basis, to the extent that their prior authorization, formulary exception requests, or appeals have not been processed by the end of the transition period and until such time as a transition has been made (either through a switch to an appropriate formulary drug or a decision on a prior authorization or exception request). This process is managed by the PBM prior authorization advocates where PBM manages prior authorizations on behalf of CHPW.

### **Requests For Exceptions or Prior Authorization**

CHPW delegates prior authorization or exception requests to the PBM.

1. The PBM processes exception requests made by the enrollee or the enrollee's authorized representative, prescribing physician, or other prescriber. The PBM will make a coverage determination as to whether to approve or deny the request. Should the PBM deny the request, the enrollee may appeal the decision.

### **Procedure For Transition Letter Generation**

The PBM automatically generates a weekly report of transition fill claims and distributes to CHPW. The PBM will identify members and generate letters to enrollees within 7 days from the date of adjudication. The letters include (1) an explanation the transition supply provided is temporary and may not be refilled unless a formulary exception is approved; (2) the enrollee

Data contained in this document is considered confidential and proprietary information and its duplication, use, or disclosure is prohibited without prior approval of Community Health Plan of Washington.

should work with CHPW as well as his or her health care provider to identify appropriate therapeutic alternatives that are on the CHPW's formulary; (3) the member has the right to request a formulary exception. In addition, Desk Procedure *DP – 126 Medicaid Transition Oversight Monitoring* details the transition fill oversight process.

## List of Appendices

A. Detailed Revision History

## Citations & References

|                                |   |      |
|--------------------------------|---|------|
| <b>CFR</b>                     |   |      |
| <b>WAC</b>                     |   |      |
| <b>RCW</b>                     |   |      |
| <b>LOB / Contract Citation</b> | <input checked="" type="checkbox"/> <b>WAHIMC</b> | § 14 |
|                                | <input type="checkbox"/> <b>BHSO</b>              |      |
|                                | <input type="checkbox"/> <b>MA</b>                |      |
|                                | <input type="checkbox"/> <b>CS</b>                |      |
| <b>Other Requirements</b>      |   |      |
| <b>NCQA Elements</b>           |   |      |

## Revision History

|                    |  |
|--------------------|--|
| <b>SME Review:</b> | 01/28/2013; 03/27/2015; 03/04/2016; 03/01/2017; 03/02/2018; 03/12/2019; 02/24/2020; 02/24/2021; 02/25/2022; 3/2/2023               |
| <b>Approval:</b>   | 04/19/2013; 04/23/2014; 04/07/2015; 03/18/2016; 03/14/2017; 03/13/2018; 03/13/2019; 03/27/2020; 03/17/2021; 03/01/2022; 03/03/2023 |

## Appendix A: Detailed Revision History

| Revision Date | Revision Description                                      | Revision Made By                  |
|---------------|---|-----------------------------------|
| 01/28/2013    | Original  | Reid Yamamoto, PharmD             |
| 04/19/2013    | Approval  | MMLT                              |
| 04/23/2014    | Approval  | MMLT                              |
| 03/27/2015    | Minor grammatical changes                                 | Mary Eckhart                      |
| 04/07/2015    | Approval  | MMLT                              |
| 03/04/2016    | Updated citations table. Minor text edits                 | Mary Eckhart                      |
| 03/18/2016    | Approval  | MMLT                              |
| 03/01/2017    | Moved to new template. Minor text updates.                | Mary Eckhart                      |
| 03/14/2017    | Approval  | MMLT                              |
| 03/02/2018    | Moved to new template                                     | Mary Eckhart                      |
| 03/13/2018    | Approval  | MMLT                              |
| 03/12/2019    | Reviewed, no changes                                      | Erin Riddle                       |
| 03/13/2019    | Approval  | Erin Riddle                       |
| 02/24/2020    | Reviewed. Minor process updates, updated citations table. | Rebecka Braband                   |
| 03/05/2020    | Reviewed  | Omar Daoud                        |
| 03/10/2020    | Department Approval                                       | Yusuf Rashid                      |
| 03/27/2020    | Approval  | CMO Cabinet                       |
| 02/24/2021    | Minor edits   | Omar Daoud                        |
| 03/17/2021    | Approval  | Yusuf Rashid                      |
| 03/17/2021    | Approval  | CMO Cabinet                       |
| 02/25/2022    | Process and citations table updates                       | Erin Riddle                       |
| 02/28/2021    | Department approval                                       | Omar Daoud                        |
| 03/01/2022    | Approval  | CMO Cabinet                       |
| 03/02/2023    | Minor updates   | Erin Riddle                       |
| 03/02/2023    | Reviewed  | Omar Daoud                        |
| 03/03/2023    | Approval  | Clinical Services Leadership Team |

Data contained in this document is considered confidential and proprietary information and its duplication, use, or disclosure is prohibited without prior approval of Community Health Plan of Washington.